or Try an Advanced Search...

    Technical Analysis for INZY - Inozyme Pharma, Inc.

    Grade Last Price % Change Price Change
    F 4.64 0.87% 0.04
    INZY closed up 0.87 percent on Wednesday, May 8, 2024, on 54 percent of normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Flat Down Up
    Historical INZY trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Earnings Movers Other 0.00%
    Fell Below 20 DMA Bearish 0.87%
    Fell Below 200 DMA Bearish 0.87%
    Earnings Movers Other 0.87%
    Gapped Down Weakness 0.87%
    Crossed Above 20 DMA Bullish -4.92%
    NR7 Range Contraction -4.92%
    Narrow Range Bar Range Contraction -4.92%
    Up 3 Days in a Row Strength -4.92%
    Older End-of-Day Signals for INZY ...

       Recent Intraday Alerts

    Alert Time
    Up 1% about 12 hours ago
    60 Minute Opening Range Breakout about 12 hours ago
    Rose Above 20 DMA about 15 hours ago
    10 DMA Support about 16 hours ago
    10 DMA Resistance about 16 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    INZY Chart by TradingView
    Basic chart:

    Profile

    Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Disease Pharmacy Molecular Biology Specialty Drugs Genetic Diseases Rare Genetic Disease Rare Genetic Diseases Recombinant Dna

    Is INZY a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 8 Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
    May 8 Inozyme Pharma GAAP EPS of -$0.38 beats by $0.02
    May 7 Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
    May 3 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Apr 9 Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Apr 8 Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
    Apr 2 Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
    Mar 28 Top 5 Health Care Stocks That May Plunge In March
    Mar 26 Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
    Mar 12 Inozyme Pharma: Q4 Earnings Insights
    See more INZY news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 7.795
    52 Week Low 2.689
    Average Volume 732,307
    200-Day Moving Average 4.66
    50-Day Moving Average 5.60
    20-Day Moving Average 4.63
    10-Day Moving Average 4.57
    Average True Range 0.32
    RSI (14) 41.52
    ADX 28.57
    +DI 15.30
    -DI 26.15
    Chandelier Exit (Long, 3 ATRs) 4.75
    Chandelier Exit (Short, 3 ATRs) 5.13
    Upper Bollinger Bands 5.11
    Lower Bollinger Band 4.15
    Percent B (%b) 0.51
    BandWidth 20.62
    MACD Line -0.28
    MACD Signal Line -0.35
    MACD Histogram 0.0705
    Fundamentals Value
    Market Cap 286.57 Million
    Num Shares 61.8 Million
    EPS -1.44
    Price-to-Earnings (P/E) Ratio -3.22
    Price-to-Sales 0.00
    Price-to-Book 2.24
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.88
    Resistance 3 (R3) 4.86 4.75 4.84
    Resistance 2 (R2) 4.75 4.69 4.77 4.83
    Resistance 1 (R1) 4.70 4.65 4.73 4.72 4.81
    Pivot Point 4.59 4.59 4.61 4.61 4.59
    Support 1 (S1) 4.54 4.53 4.57 4.56 4.47
    Support 2 (S2) 4.43 4.49 4.45 4.45
    Support 3 (S3) 4.38 4.43 4.44
    Support 4 (S4) 4.40